Abstract
Background for the introduction of the SPC legislation in Europe. Effective patent life decreased to less than 10 years. This was considered insufficient to cover the investment into research. Supplementary Protection Certificates (SPCs) to allow longer period of effective protection. Extensive case law - still unclarities in interpretation of the SPC regulation. Technological development in pharmaceutical industry - biotechnological innovation and secondary/second medical use innovation - further challenges to interpretation of the SPC regulation. Aim of the book. Structure of the book. Prior studies on the SPC system.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
